JP2011256213A5 - - Google Patents

Info

Publication number

JP2011256213A5

JP2011256213A5 JP2011211535A JP2011211535A JP2011256213A5 JP 2011256213 A5 JP2011256213 A5 JP 2011256213A5 JP 2011211535 A JP2011211535 A JP 2011211535A JP 2011211535 A JP2011211535 A JP 2011211535A JP 2011256213 A5 JP2011256213 A5 JP 2011256213A5

Authority

JP

Japan

Prior art keywords

antibody

antigen

binding fragment

composition

ige

Prior art date

2011-09-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims 37
• 239000000427 antigen Substances 0.000 claims 33
• 102000036639 antigens Human genes 0.000 claims 33
• 108091007433 antigens Proteins 0.000 claims 33
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
• 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 11
• 241000124008 Mammalia Species 0.000 claims 11
• 102000009438 IgE Receptors Human genes 0.000 claims 9
• 108010073816 IgE Receptors Proteins 0.000 claims 9
• 208000035475 disorder Diseases 0.000 claims 9
• 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 8
• 210000004027 cell Anatomy 0.000 claims 6
• 210000004408 hybridoma Anatomy 0.000 claims 6
• 229920001184 polypeptide Polymers 0.000 claims 5
• 102000004196 processed proteins & peptides Human genes 0.000 claims 5
• 108090000765 processed proteins & peptides Proteins 0.000 claims 5
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 4
• 206010020751 Hypersensitivity Diseases 0.000 claims 4
• 206010061218 Inflammation Diseases 0.000 claims 4
• 230000003213 activating effect Effects 0.000 claims 4
• 208000026935 allergic disease Diseases 0.000 claims 4
• 230000007815 allergy Effects 0.000 claims 4
• 208000006673 asthma Diseases 0.000 claims 4
• 230000000694 effects Effects 0.000 claims 4
• 230000004054 inflammatory process Effects 0.000 claims 4
• 108020003175 receptors Proteins 0.000 claims 4
• 102000005962 receptors Human genes 0.000 claims 4
• 125000003275 alpha amino acid group Chemical group 0.000 claims 3
• 201000010099 disease Diseases 0.000 claims 3
• 230000002222 downregulating effect Effects 0.000 claims 3
• 229960000470 omalizumab Drugs 0.000 claims 3
• 208000017667 Chronic Disease Diseases 0.000 claims 2
• 108010021468 Fc gamma receptor IIA Proteins 0.000 claims 2
• 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 claims 2
• 101710128966 High affinity immunoglobulin epsilon receptor subunit alpha Proteins 0.000 claims 2
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims 2
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 2
• 206010012601 diabetes mellitus Diseases 0.000 claims 2
• 229960001340 histamine Drugs 0.000 claims 2
• 230000028993 immune response Effects 0.000 claims 2
• 230000002401 inhibitory effect Effects 0.000 claims 2
• 210000004962 mammalian cell Anatomy 0.000 claims 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 201000001320 Atherosclerosis Diseases 0.000 claims 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
• 230000004913 activation Effects 0.000 claims 1
• 238000004220 aggregation Methods 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 claims 1
• 239000002246 antineoplastic agent Substances 0.000 claims 1
• 210000003719 b-lymphocyte Anatomy 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 210000003630 histaminocyte Anatomy 0.000 claims 1
• 210000005260 human cell Anatomy 0.000 claims 1
• 230000005764 inhibitory process Effects 0.000 claims 1
• 230000023404 leukocyte cell-cell adhesion Effects 0.000 claims 1
• 201000006417 multiple sclerosis Diseases 0.000 claims 1
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
• 208000011580 syndromic disease Diseases 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1